Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 622.00K | 622.00K | 603.50K | 603.50K | 994.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -40.50K | -40.50K | -18.30K | -18.30K | -17.10K |
| Total Operating Expenses | 1.31M | 1.31M | 1.47M | 1.47M | 1.96M |
| Operating Income | -1.31M | -1.31M | -1.47M | -1.47M | -1.96M |
| Income Before Tax | -767.50K | -767.50K | -2.06M | -2.06M | -2.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -767.50K | -767.50K | -2.06M | -2.06M | -2.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -767.50K | -767.50K | -2.06M | -2.06M | -2.17M |
| EBIT | -1.31M | -1.31M | -1.47M | -1.47M | -1.96M |
| EBITDA | -1.31M | -1.31M | -- | -- | -- |
| EPS Basic | -0.15 | -0.15 | -0.57 | -0.57 | -1.05 |
| Normalized Basic EPS | -0.10 | -0.10 | -0.36 | -0.36 | -0.66 |
| EPS Diluted | -0.15 | -0.15 | -0.57 | -0.57 | -1.05 |
| Normalized Diluted EPS | -0.10 | -0.10 | -0.36 | -0.36 | -0.66 |
| Average Basic Shares Outstanding | 5.02M | 5.02M | 3.60M | 3.60M | 2.06M |
| Average Diluted Shares Outstanding | 5.02M | 5.02M | 3.60M | 3.60M | 2.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |